ARTICLE | Company News
Dara BioSciences, T3D deal
June 24, 2013 7:00 AM UTC
Dara granted T3D exclusive, worldwide rights to develop and commercialize DB959 for $500,000 in initial license fees. The dual PPAR delta and gamma agonist has completed Phase I testing to treat dia...